Chimerix Acquires Oncoceutics to Expand Pipeline with Late-Stage Oncology Program
ONC201 Registrational Trial for Recurrent H3 K27M-mutant Glioma Compelling Response Rates to Date; Defined Regulatory Path to Registration Pivotal Data Anticipated in 2021 to Support Potential Registration, Addressing an Estimated Market Opportunity of Greater than $500 Million Management to Host Conference Call at 8:30 a.m. ET Today DURHAM, N.C., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that the Company has acquired Oncoceutics, Inc., a privately-held, clinical-stage biotechnology company developing imipridones, a novel
